Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps control asthma symptoms and allergic rhinitis in adults and children. GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic airway and nasal conditions. - Asthma: reduces the frequency and severity of bronchospasm episodes. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Sore throat: mild irritation. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin reactions. - Severe bronchospasm: paradoxical worsening of breathing. - Thromboembolic events: rare clot formation.

Before initiating therapy, consider the following safety measures. - Assess liver function: monitor in patients with hepatic impairment. - Avoid use in patients with known hypersensitivity to montelukast or any tablet excipients. - Use caution in patients with psychiatric disorders; monitor mood changes. - Consider dose adjustment in severe renal impairment, although no formal reduction is required. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines that affect its metabolism or plasma levels.

Major Interactions (Avoid): - Ritonavir: can increase montelukast concentrations, raising risk of side effects. - Phenobarbital: may lower montelukast exposure, reducing efficacy. - Carbamazepine: can decrease plasma levels, potentially compromising control of asthma.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly raise montelukast levels; observe for adverse effects. - Erythromycin: can increase exposure; monitor for headache or gastrointestinal upset. - Warfarin: montelukast may affect metabolism; check INR regularly when co‑administered.